KR890001521A - 서방형 신규 제약 제제물 - Google Patents
서방형 신규 제약 제제물 Download PDFInfo
- Publication number
- KR890001521A KR890001521A KR870007169A KR870007169A KR890001521A KR 890001521 A KR890001521 A KR 890001521A KR 870007169 A KR870007169 A KR 870007169A KR 870007169 A KR870007169 A KR 870007169A KR 890001521 A KR890001521 A KR 890001521A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- active compound
- solubilizer
- weight
- nonionic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 1,4 및 참조예 A에 의한 조성물이 평균 플라스마 값을 나타내는 그래프임
제2도는 실시예 3 및 참조에 B에 의한 조성물의 평균 플라스마 갑을 나타내는 그래프임,
제3도는 실시예 5에 의한 조성물 및 니페디핀을 함유하는 참조 제제물, 즉 AdalatR10mg(참조예 C)의 평균 플라스마 값을 나타내는 그래프임.
Claims (17)
- 반고상 또는 액상 비이온성 가용화제 중에 용해시키거나 분산시킨 유효 화합물을 함유시키되, 가용화제의 양(중량)을 유효 화합물의 양(중량과 적어도 동일하게 함을 특징으로 하는, 매우 낮은 용해도를 갖는 유효 화합물의 서방형 고상 제제물.
- 제1항에 있어서, 비이온성 가용화제를 폴리에틸렌글리콜의 에스테르 및 (또는) 에테르 중에서 선택한 제제물.
- 제1항 또는 제2항에 있어서, 비이온성 가용화제를 폴리에톡실화 지방산, 히드록실화 지방산 또는 지방 알코올 중에서 선택한 제제물.
- 제1항 내지 제3항 중 어느 하나의 항에 있어서, 비이온성 가용화제를 폴리에톡실화 피마자유, 폴리에톡실화 수소첨가 피마자유,피마자유로부터 채취한 폴리에톡실화 지방산 수소첨가 피마자유로부터 채취한 폴리에톡실화 지방산 중에서 선택한 제제물.
- 제4항에 있어서, 비이온성 가용화제가 수소첨가 피마자유 지방산과 옥시에틸화 글리세린과의 에스테르, 특히 CremophorRRH 40(바스프 제품)인 제제물.
- 제1항에 있어서, 유효 화합물과 가용화제의 비율이 1:1 내지 1:10 적합하기로는 1:2 내지 1:6인 제제물.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 유효 화합물이 물 중에서 1:1000(중량) 이하의 용해도를 갖고, 비이온성 가용화제 또는 물과 비이온성 가용화제의 복합물 중에서 가용화될 수 있는 제제물.
- 제1항 내지 제7항 중 어느 하나의 항에 있어서, 유효 화합물이 1개 이상의 치환 디히드로피리딘류로 되는 제제물.
- 제8항에 있어서, 치환 디히드로피리딘이 니페디핀인 제제물.
- 재8항에 있어서, 치환 디히드로피리딘이 펠로디핀인 제제물.
- 제1항 내지 제10항중 어느 한 항에 있어서, 방출을 불활성이고 다공성인 기질, 확산 지연 코우팅 또는 붕해 코우팅에 의해 조절시킨 제제물.
- 제1항 내지 제10항 중 어느 하나의 항에 있어서, 방출을 친수성 겔 시스템에 의해 조절시킨 제제물.
- 제12항에 있어서, 친수성 겔 형성 성분이 제제물의 20%-80% 중량%로 되는 제제물.
- 제12항 또는 제13항에 있어서, 친수성 겔 시스템이 히드록시프로필 메틸셀룰로오스로 되는 제제물.
- 제14항에 있어서, 히드록시프로필 메틸세룰로오스가 4%-12중량%의 히드록시프로필 함량을 갖는 제제물.
- 제12항 내지 제14항 중 어느 하나의 항에 있어서, 친수성 겔 시스템에 카르복시폴리에틸렌을 함유시킨 제제물.
- 유효 화합물을 적어도 유효 화합물과 등량(중량)의 반고상 또는 액상 비이온성 가용화제 중에 용해 또는 분산시킨 후, 혼합물을 공지된 방법으로 적합한 서방형 시스템 중에 혼입시킨 다음, 제약 투여 단위로 제제하는 것을 특징으로 하는, 매우 낮은 용해도를 갖는 유효 화합물의 서방형 고상 제제물의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8601624A SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | New pharmaceutical preparations |
SE8601624-3 | 1986-04-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890001521A true KR890001521A (ko) | 1989-03-27 |
KR950002147B1 KR950002147B1 (ko) | 1995-03-14 |
Family
ID=20364135
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR870003416A KR870009720A (ko) | 1986-04-11 | 1987-04-10 | 서방형 신규 제약 제제물 |
KR1019870007169A KR950002147B1 (ko) | 1986-04-11 | 1987-07-06 | 서방형 신규 제약 제제 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR870003416A KR870009720A (ko) | 1986-04-11 | 1987-04-10 | 서방형 신규 제약 제제물 |
Country Status (34)
Country | Link |
---|---|
US (1) | US4803081A (ko) |
EP (1) | EP0249587B1 (ko) |
JP (1) | JPH0778016B2 (ko) |
KR (2) | KR870009720A (ko) |
CN (1) | CN1025150C (ko) |
AT (1) | ATE76288T1 (ko) |
AU (1) | AU602677B2 (ko) |
CA (1) | CA1304294C (ko) |
CS (1) | CS270560B2 (ko) |
CY (1) | CY1826A (ko) |
DD (1) | DD263231A5 (ko) |
DE (1) | DE3779183D1 (ko) |
DK (1) | DK173033B1 (ko) |
DZ (1) | DZ1067A1 (ko) |
EG (1) | EG18265A (ko) |
ES (1) | ES2031929T3 (ko) |
FI (1) | FI91826C (ko) |
GR (1) | GR3005286T3 (ko) |
HK (1) | HK26795A (ko) |
HU (1) | HU204699B (ko) |
IE (1) | IE59419B1 (ko) |
IS (1) | IS1553B (ko) |
MY (1) | MY101553A (ko) |
NO (1) | NO174795B (ko) |
NZ (1) | NZ219633A (ko) |
PH (1) | PH22494A (ko) |
PL (1) | PL265078A1 (ko) |
PT (1) | PT84663B (ko) |
SE (1) | SE8601624D0 (ko) |
SG (1) | SG4295G (ko) |
SU (1) | SU1743332A3 (ko) |
UA (1) | UA12336A (ko) |
YU (1) | YU47258B (ko) |
ZA (1) | ZA871911B (ko) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
NO883326L (no) * | 1987-08-11 | 1989-02-13 | Bayer Ag | Dhp-retard-tilberedning. |
DE3738236A1 (de) * | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | Beisskapsel |
GB2222770B (en) * | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
US5006344A (en) * | 1989-07-10 | 1991-04-09 | E. R. Squibb & Sons, Inc. | Fosinopril tablet formulations |
HU208491B (en) * | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
US6262022B1 (en) | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
US5834496A (en) * | 1991-12-02 | 1998-11-10 | Sepracor, Inc. | Methods for treating hypertension using optically pure S(-) felodipine |
US5681812A (en) * | 1991-12-10 | 1997-10-28 | Rush Presbyterian-St. Luke's Medical Center | Methods and compositions for reducing multidrug resistance |
AU3243393A (en) * | 1991-12-10 | 1993-07-19 | Rush - Presbyterian - St. Luke's Medical Center | Methods and compositions for reducing multi-drug resistance |
GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
JP3631490B2 (ja) | 1992-05-13 | 2005-03-23 | ノバルティス ファーマ株式会社 | シクロスポリン含有眼科用組成物 |
US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
DK0661045T3 (da) | 1992-09-18 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Hydrogelpræparat med forsinket frigivelse |
JP3598049B2 (ja) * | 1992-09-18 | 2004-12-08 | 山之内製薬株式会社 | ハイドロゲル徐放性製剤 |
DK0589843T3 (da) | 1992-09-25 | 2002-04-02 | Novartis Ag | Cyclosporinholdige farmaceutiske præparater |
BE1006990A5 (nl) * | 1993-04-22 | 1995-02-07 | Univ Gent | Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen. |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
US20060263428A1 (en) * | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
US6676967B1 (en) * | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
DE4340781C3 (de) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US6093420A (en) | 1996-07-08 | 2000-07-25 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
ES2229473T3 (es) | 1997-01-30 | 2005-04-16 | Novartis Ag | Composiciones farmaceuticas sin aceite que contienen ciclosporina a. |
US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
AR017512A1 (es) | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
SE9902742D0 (sv) * | 1999-07-20 | 1999-07-20 | Astra Ab | New pharmaceutical formultion |
NZ511900A (en) * | 1999-09-30 | 2003-06-30 | Penwest Pharmaceuticals Co | Sustained release matrix systems for highly soluble drugs |
FR2802424B1 (fr) * | 1999-12-17 | 2002-02-15 | Adir | Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale |
GB0001449D0 (en) * | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
CZ301790B6 (cs) | 2000-04-11 | 2010-06-23 | Sankyo Company Limited | Farmaceutický prípravek obsahující blokátor vápníku |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
WO2002056883A1 (en) * | 2001-01-18 | 2002-07-25 | Wockhardt Limited | Preparation of micron-size felodipine particles by microfluidization |
DE60219478T2 (de) * | 2001-07-06 | 2008-01-03 | Endo Pharmaceuticals Inc. | Orale gabe von 6-hydroxy-oxymorphon als analgetikum |
ATE376826T1 (de) * | 2001-09-28 | 2007-11-15 | Mcneil Ppc Inc | Darreichungsformen zur modifizierten freisetzung |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
TWI324074B (en) * | 2001-10-09 | 2010-05-01 | Bristol Myers Squibb Co | Flashmelt oral dosage formulation |
US6726931B2 (en) * | 2002-04-08 | 2004-04-27 | Standard Chem. & Pharm. Co., Ltd. | Process for preparing oral sustained-release formulation of felodipine |
CN100553625C (zh) | 2002-04-09 | 2009-10-28 | 弗拉梅技术公司 | 活性成分微囊的口服混悬液 |
ATE407674T1 (de) | 2002-04-09 | 2008-09-15 | Flamel Tech Sa | Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin |
US20030211149A1 (en) * | 2002-05-07 | 2003-11-13 | Sherman Bernard Charles | Extended release tablets comprising felodipine |
JP4563642B2 (ja) * | 2002-05-31 | 2010-10-13 | ワトソン ラボラトリーズ、インコーポレイテッド | 医薬製剤 |
FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
US20080051411A1 (en) * | 2002-12-17 | 2008-02-28 | Cink Russell D | Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof |
JP2006511541A (ja) * | 2002-12-17 | 2006-04-06 | アボット ゲーエムベーハー ウント カンパニー カーゲー | フェノフィブル酸、その生理学的に許容し得る塩または誘導体を含有してなる製剤 |
US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
US20050032879A1 (en) * | 2003-08-07 | 2005-02-10 | Temple Okarter | Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
US20080152714A1 (en) * | 2005-04-08 | 2008-06-26 | Yi Gao | Pharmaceutical Formulations |
DK1915137T3 (da) * | 2005-08-10 | 2013-11-04 | Add Advanced Drug Delivery Technologies Ltd | Oralt præparat med kontrolleret frisætning |
TW200736245A (en) * | 2005-11-29 | 2007-10-01 | Sankyo Co | Acid addition salts of optically active dihydropyridine derivatives |
TW200806648A (en) * | 2005-11-29 | 2008-02-01 | Sankyo Co | Acid addition salts of dihydropyridine derivatives |
CN101103964B (zh) * | 2006-07-14 | 2010-09-29 | 海南盛科生命科学研究院 | 一种含有非洛地平的缓释制剂及其制备方法 |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
US9419566B2 (en) | 2011-04-20 | 2016-08-16 | Freescale Semiconductor, Inc. | Amplifiers and related integrated circuits |
CN104997750B (zh) * | 2015-07-30 | 2018-03-20 | 杭州康恩贝制药有限公司 | 一种非洛地平缓释片及其制备方法 |
US9687475B1 (en) | 2016-03-24 | 2017-06-27 | Ezra Pharma Llc | Extended release pharmaceutical formulations with controlled impurity levels |
US9675585B1 (en) | 2016-03-24 | 2017-06-13 | Ezra Pharma | Extended release pharmaceutical formulations |
CN109200026B (zh) * | 2017-07-03 | 2021-01-05 | 北京四环科宝制药有限公司 | 一种非洛地平缓释片及其制备方法 |
AU2019285170A1 (en) | 2018-06-14 | 2021-01-28 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2714065A1 (de) * | 1977-03-30 | 1978-10-12 | Boehringer Mannheim Gmbh | Instillationszubereitung |
JPS5495721A (en) * | 1978-01-11 | 1979-07-28 | Nippon Kayaku Co Ltd | Nifedipine preparation |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
JPS58109412A (ja) * | 1981-12-23 | 1983-06-29 | Toa Eiyou Kagaku Kogyo Kk | ニフエジピン固形製剤 |
DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
DE3400106A1 (de) * | 1984-01-04 | 1985-07-11 | Klaus-Dieter Dr. 3550 Marburg Bremecker | Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung |
KR850700212A (ko) * | 1984-03-21 | 1985-12-26 | 죠지 드모트 | 서방성 약제학적 캼셀제 |
JPS618A (ja) * | 1984-06-09 | 1986-01-06 | Sawai Seiyaku Kk | ニフエジピン含有製剤 |
IT1178511B (it) * | 1984-09-14 | 1987-09-09 | Pharmatec Spa | Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio |
IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
-
1986
- 1986-04-11 SE SE8601624A patent/SE8601624D0/xx unknown
-
1987
- 1987-03-10 PH PH35003A patent/PH22494A/en unknown
- 1987-03-12 YU YU40787A patent/YU47258B/sh unknown
- 1987-03-16 NZ NZ219633A patent/NZ219633A/xx unknown
- 1987-03-16 AU AU70043/87A patent/AU602677B2/en not_active Expired
- 1987-03-16 ZA ZA871911A patent/ZA871911B/xx unknown
- 1987-03-22 EG EG171/87A patent/EG18265A/xx active
- 1987-03-23 NO NO871199A patent/NO174795B/no unknown
- 1987-03-25 EP EP87850098A patent/EP0249587B1/en not_active Expired - Lifetime
- 1987-03-25 ES ES198787850098T patent/ES2031929T3/es not_active Expired - Lifetime
- 1987-03-25 AT AT87850098T patent/ATE76288T1/de not_active IP Right Cessation
- 1987-03-25 DE DE8787850098T patent/DE3779183D1/de not_active Expired - Lifetime
- 1987-03-26 DK DK198701549A patent/DK173033B1/da not_active IP Right Cessation
- 1987-04-03 US US07/034,500 patent/US4803081A/en not_active Expired - Lifetime
- 1987-04-07 DZ DZ870056A patent/DZ1067A1/fr active
- 1987-04-07 MY MYPI87000450A patent/MY101553A/en unknown
- 1987-04-07 CA CA000533985A patent/CA1304294C/en not_active Expired - Lifetime
- 1987-04-09 DD DD87301670A patent/DD263231A5/de unknown
- 1987-04-09 IE IE92587A patent/IE59419B1/en not_active IP Right Cessation
- 1987-04-09 PL PL1987265078A patent/PL265078A1/xx unknown
- 1987-04-10 JP JP62087250A patent/JPH0778016B2/ja not_active Expired - Lifetime
- 1987-04-10 UA UA4202349A patent/UA12336A/uk unknown
- 1987-04-10 SU SU874202349A patent/SU1743332A3/ru active
- 1987-04-10 PT PT84663A patent/PT84663B/pt unknown
- 1987-04-10 KR KR870003416A patent/KR870009720A/ko not_active Application Discontinuation
- 1987-04-10 HU HU871622A patent/HU204699B/hu unknown
- 1987-04-10 IS IS3214A patent/IS1553B/is unknown
- 1987-04-10 FI FI871585A patent/FI91826C/fi not_active IP Right Cessation
- 1987-04-10 CS CS872587A patent/CS270560B2/cs not_active IP Right Cessation
- 1987-04-10 CN CN87102758A patent/CN1025150C/zh not_active Expired - Lifetime
- 1987-07-06 KR KR1019870007169A patent/KR950002147B1/ko not_active IP Right Cessation
-
1992
- 1992-07-29 GR GR920401616T patent/GR3005286T3/el unknown
-
1995
- 1995-01-11 SG SG4295A patent/SG4295G/en unknown
- 1995-03-02 HK HK26795A patent/HK26795A/xx not_active IP Right Cessation
- 1995-12-01 CY CY182695A patent/CY1826A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890001521A (ko) | 서방형 신규 제약 제제물 | |
JP3947215B2 (ja) | 安定な局所レチノイド組成物 | |
US3749773A (en) | Gelled steroid ointment | |
UA39896C2 (uk) | Фармацевтична або ветеринарна композиція мупіроцину та спосіб її приготування | |
FR2795960A1 (fr) | Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions | |
JPH02235817A (ja) | 新規シクロスポリン製剤 | |
JO2324B1 (en) | Pharmaceutical compounds for topical oral use | |
JPH0463043B2 (ko) | ||
EP0471084B1 (en) | Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic | |
US5683704A (en) | Cosmetic composition | |
FR2491333A1 (fr) | Compositions pharmaceutiques administrables par voie topique et contenant des steroides anti-inflammatoires | |
SK283216B6 (sk) | Prípravok obsahujúci cyklosporín a spôsob jeho prípravy | |
KR930000048B1 (ko) | 연질 캡슐용 폴리프레닐계 화합물 조성물 | |
US6979454B1 (en) | Biologically active composition | |
EP0372527B1 (en) | Topical compositions containing diclofenac | |
JP2621976B2 (ja) | アントラリン・ステロール錯体、その製法および治療・化粧用途 | |
EP0322197B1 (en) | New dithranol compositions | |
JPH0725735A (ja) | 含嗽剤 | |
FI118953B (fi) | Ulkoisesti käytettävä, nimesulidia käsittävä tulehdusta torjuva aine | |
JPH0371409B2 (ko) | ||
JP3280712B2 (ja) | 皮膚外用剤 | |
JP2020509042A (ja) | イデベノンのための経粘膜送達系 | |
JPH07258082A (ja) | ビタミンe製剤組成物 | |
JPH04338333A (ja) | プロスタグランジンe1脂肪乳剤 | |
RU2148998C1 (ru) | Фармацевтическая или ветеринарная композиция (варианты) и способ получения композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090121 Year of fee payment: 15 |
|
EXPY | Expiration of term |